（一）出席会议情况 益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（王小岩） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，2024 年本人严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董 事管理办法》《独立董事工作制度》等法律、法规以及《公司章程》的规定，恪 尽职守，勤勉尽责，充分发挥独立董事的独立作用，维护了公司及全体股东的利 益。现将 2024 年度本人履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 王小岩，男，中国国籍，无境外永久居留权，1976 年 2 月出生，工商管理 硕士，注册会计师、注册税务师、国际注册内部审计师。曾任德勤华永会计师事 务所高级审计员、广西丰林木业集团股份有限公司总裁助理、广西玉柴机器集团 有限公司审计总监、广州珠江云峰投资控股有限公司财务总监。现任蓝河乳业集 团有限公司财务总监。自 2024 年 6 月 26 日起，担任公司独立董事、审计委员会 召集人、提名委员会委员。 （二）履职独立性情况 作为公司独立董事，本人及本人的直系亲属、主要社会关系均不在公司或其 附属企业任职，不直接或间接有公司股份 ...

2024 年度独立董事履职报告（易兰广） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，本人任 职于 2024 年 6 月 25 日第四届董事会任期届满。任职期内，本人严格按照《公司 法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法 规以及《公司章程》《独立董事工作制度》的规定，恪尽职守，勤勉尽责，充分 发挥独立董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人 履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 易兰广，男，中国国籍，无永久境外居留权，1976 年 12 月出生，管理科学 与工程博士，高级会计师职称。曾任三一重工有限公司子公司财务总监，国药控 股湖南有限公司副总经理、财务总监，九州通医药集团股份有限公司财务管理总 部部长。现任湖南泽华私募股权基金管理有限公司执行董事、总经理。2021 年 3 月 29 日至 2024 年 6 月 25 日期间，担任公司独立董事、审计委员会召集人、提 名委员会、薪酬与考核委员会委员。 （二）履职独立性情况 作为公司独立董事，本人及本人的直系亲属、主要社会关系均不在公司或其 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 6,009,043,521.27, representing a year-on-year increase of 0.64% compared to CNY 5,970,923,210.35 in the same period last year[4] - Net profit attributable to shareholders of the listed company reached CNY 449,493,528.80, marking a 10.51% increase from CNY 406,753,106.09 in the previous year[4] - Basic earnings per share rose to CNY 0.37, up 12.12% from CNY 0.33 in the previous year[4] - Net profit for Q1 2025 was ¥493,549,281.07, up 10.6% from ¥445,951,883.35 in Q1 2024[25] - Earnings per share (EPS) increased to ¥0.37 in Q1 2025 from ¥0.33 in Q1 2024, representing a growth of 12.1%[25] - The company reported an operating profit of ¥650,541,861.92, which is an increase from ¥593,522,472.65 in the previous year, reflecting a growth of 9.6%[24] Cash Flow - The net cash flow from operating activities significantly increased by 71.42%, amounting to CNY 1,114,385,691.58 compared to CNY 650,107,205.26 in the same period last year[4] - Cash inflow from operating activities totaled $6,700,021,854.84, an increase of 8.1% compared to $6,196,262,045.28 in the previous period[28] - The net cash flow from operating activities was $1,114,385,691.58, a significant increase from $650,107,205.26 in the prior period[28] - Total cash outflow for operating activities was $5,585,636,163.26, slightly up from $5,546,154,840.02 in the previous period[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 27,786,561,356.06, a decrease of 0.67% from CNY 27,974,736,950.35 at the end of the previous year[5] - The equity attributable to shareholders of the listed company increased by 4.28%, reaching CNY 11,185,232,095.24 compared to CNY 10,725,687,023.42 at the end of the previous year[5] - The company's total liabilities decreased to ¥15,893,358,192.95 from ¥16,581,173,472.42, a reduction of approximately 4.15%[20] - The total current liabilities decreased to RMB 12,103,474,750.82 from RMB 12,598,073,700.81, indicating a reduction of about 3.9%[19] - The company's long-term assets totaled RMB 11,911,046,281.79, down from RMB 12,118,954,736.84, reflecting a decrease of approximately 1.7%[19] Inventory and Receivables - The accounts receivable decreased to RMB 1,831,522,834.46 from RMB 2,123,984,911.43, showing a decline of approximately 13.8%[18] - Inventory levels decreased to RMB 4,371,628,158.53 from RMB 4,528,102,252.16, a reduction of about 3.5%[18] - The company accelerated the collection of accounts receivable, contributing to the significant increase in cash flow from operating activities[9] - The company reported a significant increase in other receivables, rising to RMB 556,953,713.36 from RMB 477,936,663.36, an increase of about 16.4%[18] Store Operations - The company opened 94 new stores in Q1 2025, including 26 self-built stores and 68 franchise stores, while closing 84 stores, resulting in a net increase of 10 stores, totaling 14,694 stores[14] Investment Income - The company reported an investment income of CNY 27,186,162.03, which is related to its daily operating activities[8] - The company’s investment income rose to ¥27,186,162.03 from ¥14,930,288.87, indicating an increase of approximately 81.5%[24] Other Financial Metrics - Non-recurring gains and losses for the period amounted to CNY 11,508,186.24 after tax and minority interests[7] - Other comprehensive income after tax for Q1 2025 was ¥9,609,750.00, a significant recovery from a loss of ¥44,204,850.00 in Q1 2024[25] - The weighted average return on net assets was 4.02%, slightly down from 4.06% in the previous year[5] - The company's cash and cash equivalents increased to RMB 3,964,045,471.35 from RMB 3,578,925,577.22, reflecting a growth of approximately 10.8%[18] - The company maintained a stable goodwill value of RMB 4,768,942,152.07, unchanged from the previous period[19]

益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（颜爱民） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，本人 任职于 2024 年 6 月 25 日第四届董事会任期届满。任职期内，本人严格按照《公 司法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法 规以及《公司章程》《独立董事工作制度》的规定，恪尽职守，勤勉尽责，充分 发挥独立董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人 履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 颜爱民，男，中国国籍，无永久境外居留权，1963 年 1 月出生，管理学博 士。中南大学商学院教授、博士生导师、中南大学人力资源研究中心（国家 CTTI 智库）主任/首席专家。曾任中南工业大学管理科学与工程系讲师、中南大学商 学院副教授，湖南千金药业股份有限公司独立董事、湖南黄金集团有限责任公司 外部董事。现任中南大学商学院二级教授、博士生导师、中南大学人力资源研究 中心（国家 CTTI 智库）主任/首席专家，上海肇民新材料科技股份有限公司 （301000）与湖南松井新材料股份有限公 ...

一、 基本情况 （一）工作履历、专业背景及兼职情况 益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（王红霞） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，本人任 职于 2024 年 6 月 25 日第四届董事会任期届满。任职期内，本人严格按照《公司 法》《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等法律法 规以及《公司章程》《独立董事工作制度》的规定，恪尽职守，勤勉尽责，充分 发挥独立董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人 履行独立董事职责的情况汇报如下： 王红霞，女，中国国籍，无永久境外居留权，1979 年 7 月出生，博士后学 历，律师职称。现任中南大学副教授、博士生导师。2021 年 3 月 29 日至 2024 年 6 月 25 日期间，担任公司独立董事、提名委员会召集人、审计委员会委员。 （二）履职独立性情况 作为公司独立董事，本人及本人的直系亲属、主要社会关系均不在公司或其 附属企业任职，不直接或间接持有公司股份，不在直接或间接持有公司已发行股 份 5%及以上或公司前五名股东单位任职，不在公司控股股东、实际控制人的附 属企业 ...

益丰大药房连锁股份有限公司 2024 年度独立董事履职报告（秦拯） 作为益丰大药房连锁股份有限公司（以下简称"公司"）的独立董事，2024 年本人严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董 事管理办法》《独立董事工作制度》等法律、法规以及《公司章程》的规定，恪 尽职守，勤勉尽责，充分发挥独立董事的独立作用，维护了公司及全体股东的利 益。现将 2024 年度本人履行独立董事职责的情况汇报如下： 一、 基本情况 （一）工作履历、专业背景及兼职情况 秦拯，男，中国国籍，无境外永久居留权，1969 年出生，工学博士、管理 学博士后，湖南大学教授、博士生导师，湖南大学大数据处理与行业应用研究中 心主任、大数据研究与应用湖南省重点实验室主任，教育部网络空间安全教指委 委员、中国工程教育专业认证专家，中国计算机学会大数据专委会委员，中国人 工智能学会智能服务专委会委员、人工智能与安全专委会委员，湖南制造强省建 设专家咨询委员会委员、湖南省网络安全与信息化专家咨询委员会委员。现任湖 南梦洁股份有限公司（002397）、拓维信息系统股份有限公司（002261）独立董 事。自 2024 年 6 月 26 日 ...

益丰药房（603939）公告，2024年度实现归属于母公司净利润15.29亿元，同比增长8.26%。公司拟向全 体股东每股派发现金红利0.4元(含税)，合计拟派发现金红利4.85亿元(含税)。 ...

Core Viewpoint - The company is utilizing idle raised funds for entrusted financial management to enhance fund efficiency and increase returns while ensuring that the original purpose of the raised funds remains unchanged [3][13]. Group 1: Entrusted Financial Management Details - The amount for entrusted financial management is 212 million yuan [4]. - The source of the funds is idle raised funds [5]. - The company has received approval from the China Securities Regulatory Commission for issuing convertible bonds totaling 1.797 billion yuan, with a net amount of approximately 1.780 billion yuan after deducting issuance costs [6]. Group 2: Approval and Procedures - The board of directors approved the proposal for using idle raised funds for entrusted financial management during the 15th meeting of the 5th board on April 15, 2025, allowing a maximum of 300 million yuan for this purpose [8]. - The investment products will be selected based on high safety and liquidity, with a validity period of 12 months for the approved amount [8]. Group 3: Risk Management and Control Measures - The company will conduct strict evaluations of investment products, focusing on low-risk financial products, while acknowledging potential market volatility risks [9][10]. - Measures include maintaining an investment ledger, regular audits by the audit department, and oversight by independent directors and supervisors [10][11]. Group 4: Impact on the Company - The investment in short-term financial products will not affect the normal operation of the company's main business or its daily cash flow needs [13]. - This strategy aims to generate additional investment returns, enhancing the company's performance and providing better returns for shareholders [13].

Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) closed at 2534.82 points, with a trading volume of 4.515 billion yuan, reflecting a slight increase of 0.12% [1] - Over the past month, the CS Internet Medical Index has decreased by 5.58%, while it has increased by 14.02% over the past three months and by 7.06% year-to-date [1] - The index includes representative companies that provide hardware, software, or services for medical informationization and intelligence, with a base date of June 29, 2012, set at 1000.0 points [1] Group 2 - The top ten weighted companies in the CS Internet Medical Index are: Yifeng Pharmacy (6.75%), Daclin (6.71%), Laobaixing (6.14%), Wandong Medical (5.6%), Yixintang (5.58%), Jiuzhoutong (5.43%), Haier Biomedical (5.37%), Lepu Medical (5.32%), Yuyue Medical (5.18%), and Aier Eye Hospital (5.14%) [1] - The market share of the CS Internet Medical Index holdings is divided between Shenzhen Stock Exchange (50.91%) and Shanghai Stock Exchange (49.09%) [1] - In terms of industry composition, the holdings of the CS Internet Medical Index consist of 70.63% in pharmaceuticals and healthcare, 25.60% in information technology, and 3.77% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to calculation and maintenance guidelines [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]